Last reviewed · How we verify
NCT05050929: RAPPLE
RAPid SimPLE Targeted Radiation Treatment for Brain Metastases
Phase 2 trial testing Targeting All Brain Metastases in Brain Metastases, Adult in 100 participants. Currently enrolling.
30 December 2026
Quick facts
| Lead sponsor | British Columbia Cancer Agency |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 100 |
| Start date | 1 July 2022 |
| Primary completion | 30 December 2026 |
| Estimated completion | 30 December 2027 |
| Sites | 6 locations across Canada |
Drugs / interventions tested
- Targeting All Brain Metastases
Conditions studied
- Brain Metastases, Adult — all drugs for Brain Metastases, Adult →
Sponsor
British Columbia Cancer Agency
Who can join
Adults 18 to 100, any sex, with Brain Metastases, Adult. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of the study is to show that rapid, simple targeted radiotherapy to brain metastases with 8 Gy / 1 is non-inferior to 20 Gy / 5 in terms of overall survival for patients with poor prognosis.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
RAPid simPLE (RAPPLE) Targeted Radiation Treatment Versus Whole Brain Radiation Therapy: A Retrospective Cohort Study of Matched Patients With Brain Metastases and Poor Prognosis
Parmar G, Kong T, Musoke R, Hamm J, et al · · 2026
Verify or expand the search:
- PubMed search for NCT05050929
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Brain Metastases, Adult
Currently open trials in the same condition.
- NCT07448662 — Local Treatment Strategies for Brain Metastases of Colorectal Cancer · active not recruiting
- NCT07198256 — AI-assisted Diagnosis of Malignant Brain Tumors · recruiting
- NCT06401824 — Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases · Phase 2 · recruiting
- NCT06209567 — A Study of 68Ga-PSMA-11 PET Scans in People With Brain Tumors · EARLY_PHASE1 · active not recruiting
- NCT06280300 — Multi-disciplinary Care for Brain Metastases · NA · recruiting
Other British Columbia Cancer Agency trials
Trials by the same sponsor.
- NCT07295171 — HELP Study - Towards High Throughput and Efficient Long-axial PET With Oral [18F]FDG · NA · recruiting
- NCT07291895 — High Dose Radiotherapy for Palliation (Hi-D) · NA · not yet recruiting
- NCT06918951 — Stereotactic Radiotherapy Versus Palliative Conventional Radiotherapy for Oligoprogressive Metastatic Cancers · NA · recruiting
- NCT07210749 — Radiotherapy 12Gy in 6 Fractions For Orbital Lymphoma · NA · not yet recruiting
- NCT06835725 — Phase II Randomized Trial of 2 Versus 5 Fraction Prostate Stereotactic Ablative Radiotherapy for Intermediate Risk Prost · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05050929 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by British Columbia Cancer Agency
- Last refreshed: 17 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05050929.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing